| __timestamp | CymaBay Therapeutics, Inc. | Merus N.V. |
|---|---|---|
| Wednesday, January 1, 2014 | 8185000 | 3852327 |
| Thursday, January 1, 2015 | 8871000 | 839656 |
| Friday, January 1, 2016 | 9645000 | 4478145 |
| Sunday, January 1, 2017 | 12387000 | 16432324 |
| Monday, January 1, 2018 | 14381000 | 11890871 |
| Tuesday, January 1, 2019 | 19238000 | 34110000 |
| Wednesday, January 1, 2020 | 17425000 | 35781000 |
| Friday, January 1, 2021 | 23040000 | 40896000 |
| Saturday, January 1, 2022 | 25116000 | 52200000 |
| Sunday, January 1, 2023 | 51953000 | 59836000 |
Cracking the code
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. CymaBay Therapeutics, Inc. and Merus N.V., two prominent players, have shown distinct trends in their SG&A expenses from 2014 to 2023. Over this period, CymaBay's SG&A costs increased by over 500%, peaking at approximately $52 million in 2023. In contrast, Merus N.V. saw a more dramatic rise, with expenses surging by nearly 700%, reaching around $60 million in the same year.
While both companies have seen significant growth in their SG&A expenses, Merus N.V. consistently outpaced CymaBay, particularly from 2019 onwards. This trend suggests a more aggressive expansion strategy by Merus. Investors and industry analysts should consider these financial dynamics when evaluating the operational efficiency and strategic direction of these biotech firms.
Breaking Down SG&A Expenses: Novartis AG vs Merus N.V.
SG&A Efficiency Analysis: Comparing Vertex Pharmaceuticals Incorporated and CymaBay Therapeutics, Inc.
Comparing SG&A Expenses: GSK plc vs CymaBay Therapeutics, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Axsome Therapeutics, Inc. and Merus N.V.
Selling, General, and Administrative Costs: Verona Pharma plc vs Merus N.V.
Cost Management Insights: SG&A Expenses for Ultragenyx Pharmaceutical Inc. and CymaBay Therapeutics, Inc.
Selling, General, and Administrative Costs: CymaBay Therapeutics, Inc. vs Veracyte, Inc.
Selling, General, and Administrative Costs: CymaBay Therapeutics, Inc. vs Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Soleno Therapeutics, Inc.
CymaBay Therapeutics, Inc. vs Geron Corporation: SG&A Expense Trends
Breaking Down SG&A Expenses: CymaBay Therapeutics, Inc. vs MiMedx Group, Inc.
Cost Management Insights: SG&A Expenses for Merus N.V. and Mesoblast Limited